Latest Market Access News

American Tungsten & Antimony (ASX: AT4) has set up a Level 1 ADR program with Deutsche Bank, paving the way for its planned Nasdaq listing in Q2 2026 and opening U.S. dollar trading access for American investors.

EVE Health Group has appointed Ben Rohr as CEO, shifting Damian Wood to focus on regulatory and clinical affairs, aiming to sharpen commercial execution amid ongoing product rollouts.

TruScreen Group has met its FY2026 revenue guidance with a 41% jump in product sales, while investing heavily in new markets and pursuing a major UNITAID funding bid that could reshape its medium-term outlook.

Unico Silver has reported a 143% surge in its Joaquin project's mineral resource to 167 million ounces silver equivalent, reinforcing its status as a major silver developer. The company also progressed key pre-feasibility studies and expanded its investor reach with a US OTCQB listing.

EBR Systems secures Priority Review from Australia's TGA for its wireless cardiac pacing system, fast-tracking regulatory approval and expanding access for heart failure patients. This follows strong US commercial momentum after FDA approval.

Elixir Energy has completed its Lorelle-3/3H appraisal well with exceptional gas-condensate pay and the longest lateral drilled in the Taroom Trough. The company enters production testing phase fully funded with $22.3 million liquidity and a $10 million R&D-backed debt facility.

Tusker Minerals Ltd has seen its TSKO securities suspended from ASX quotation immediately due to non-compliance with listing rules. The suspension applies solely to this security class while the company works to meet regulatory requirements.

BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.

4DMedical lands a contract with pharma giant GSK, gains UKCA certification for its CT:VQ™ lung imaging technology, and joins the S&P/ASX 200, marking a significant step in its global expansion.

Kinetiko Energy is advancing a staged development strategy to unlock its 6 trillion cubic feet gas resource in South Africa, targeting first revenues within 18 months through a capital-efficient, risk-managed approach.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.